Zymeworks Inc (NYSE:ZYME) has been given a consensus rating of “Buy” by the nine research firms that are covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $25.00.
Several research firms have commented on ZYME. Citigroup lowered Zymeworks from a “buy” rating to a “neutral” rating in a research report on Wednesday, June 6th. Raymond James raised their price objective on Zymeworks from $22.00 to $27.00 and gave the company an “outperform” rating in a research report on Tuesday, June 5th. Wells Fargo & Co raised their price objective on Zymeworks from $20.00 to $37.00 and gave the company an “outperform” rating in a research report on Monday, June 4th. ValuEngine raised Zymeworks from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. Finally, Canaccord Genuity raised their price objective on Zymeworks from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, May 16th.
Large investors have recently added to or reduced their stakes in the business. Stanley Laman Group Ltd. purchased a new stake in shares of Zymeworks during the first quarter worth about $439,000. Perceptive Advisors LLC increased its position in shares of Zymeworks by 6.4% during the fourth quarter. Perceptive Advisors LLC now owns 777,497 shares of the company’s stock worth $5,549,000 after acquiring an additional 46,729 shares during the last quarter. Finally, PenderFund Capital Management Ltd. purchased a new stake in shares of Zymeworks during the first quarter worth about $5,360,000. 8.09% of the stock is currently owned by institutional investors.
Zymeworks (NYSE:ZYME) last issued its earnings results on Tuesday, May 1st. The company reported ($0.83) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.15). Zymeworks had a negative net margin of 30.41% and a negative return on equity of 16.07%. The firm had revenue of $0.04 million during the quarter. analysts predict that Zymeworks will post -2.55 EPS for the current fiscal year.
Zymeworks Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer.
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.